Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases. The company utilizes its proprietary XmAb protein engineering platform to design Fc domains that enhance antibody properties, such as bispecific structure, extended half-life, and improved cytotoxicity. Its pipeline includes CD3 and CD28 bispecific antibodies for oncology and autoimmune indications, as well as multi-specific formats like the XmAb 2+1 bispecific antibody. Key clinical-stage candidates include xaluritamig, XmAb819, XmAb541, XmAb808, zaltenibart, XmAb942, plamotamab, and XmAb657. Xencor generates revenue through licensing and collaboration agreements with partners such as Amgen, Alexion, and Incyte, who develop and market medicines using XmAb technologies, including Ultomiris and Monjuvi. The company also advances trispecific antibody formats and engages in research to expand the functionality of its protein engineering platforms.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage xencor.com
Sector Healthcare IR page investors.xencor.com
Tags
antibody therapeutics, bispecific antibodies, fc engineering, oncology, autoimmune diseases, protein engineering, t-cell engagers, clinical-stage, XmAb, Xtend, xaluritamig, XmAb819, XmAb541, XmAb808, zaltenibart, XmAb942, plamotamab, XmAb657, XmAb412, Ultomiris, ravulizumab-cwvz, Monjuvi, tafasitamab-cxix, Minjuvi, tafasitamab, Obexelimab, Teropavimab, zinlirvimab, Tobevibart, ASP2138, JNJ-9401, JNJ-1493
Press page —

Metrics

Valuation  
Market cap $ 2.977B
Market cap (USD) $ 2.977B
P/E -25.04
PEG —
P/BV 5.31
P/S 14.85
P/OCF -17.27
P/FCF -16.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.0%
ROI -12.2%
ROIC -17.6%
Profit margin -73.2%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 17.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 125.576M 110.493M 168.338M 164.579M 275.111M 122.7M 156.7M 40.603M — — — — — 9.524M
Net profit -91.923M -232.618M -126.087M -55.181M 82.631M -69.333M 26.875M -70.409M -48.925M 23.625M -17.592M -16.422M 84.506M -8.594M
Free cash flow -138.267M -208.285M 66.663M -14.009M -30.152M -15.543M 57.021M -86.968M -38.994M 93.11M 24.736M -22.131M -5.589M -11.093M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 15.31 22.98 21.23 26.04 40.12 43.63 34.39 36.16 21.92 26.32 14.62 16.04 9.14 —
Price performance 12m -0.33 0.08 -0.18 -0.35 -0.08 0.27 -0.05 0.65 -0.17 0.8 -0.09 0.75 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 8.62M 1.14M 10.2M 21.6M 11.4M 66.4M 29M 11.3M 60.8M 29.3M
↳ YoY growth +19,481.8% -86.7% +792.0% +111.8% -47.0% +480.1% -56.3% -61.1% +439.0% -51.8%
↳ 5y CAGR +26.4% +180.2% +48.7% +204.1% +50.4% +91.0% +2.1% +23.0% +20.7%
Borrowings, current (USD) — — — — — — 0.00 6.33M 48.4M 43.3M
Borrowings, non-current (USD) — — — — — — 0.00 14.6M 115M 76.5M
Lease liabilities (USD) — — — 10.7M 11.6M 34M 59.6M 62.5M 68.3M 68M
Cash and deposits (USD) 14.5M 16.5M 26.2M 50.3M 164M 143M 53.9M 53.8M 40.9M 54.1M
Intangible assets (USD) 10.4M 11.1M 12M 14.4M 16M 16.5M 18.5M 18.7M 18.5M 8.39M
Right-of-use assets (USD) — — — 9.38M 10.6M 31.7M 34.4M 34M 38.3M 37.6M
Net debt (borrowings + leases - cash) (USD) — — — — — — 5.69M 29.6M 191M 134M
Cash flow detail
Operating cash flow (USD) 94.6M -33.7M -79.8M 64.4M -5M -16.9M 24.5M 85.1M -202M -135M
Purchases of property, plant and equipment (USD) -1.51M -5.31M -7.21M -7.35M -10.5M -13.3M -38.5M -18.4M -6.1M -3.15M
Purchases of intangible assets (USD) -1.5M -1.97M -1.94M -3.69M -3.23M -2.68M -4.91M -2.8M -3.42M 0.00
Change in receivables (cash effect) (USD) — — — — — — — 19.8M -32.7M 28.7M
Change in payables (cash effect) (USD) -2.52M 2.99M -3.07M 6.39M -1.24M 5.05M -3.91M 3.83M 2.85M -3.95M
Interest paid (cash effect) (USD) -21,000 -13,000 -16,000 -11,000 -15,000 -14,000 -13,000 -22,000 -33,000 -5,000
Income taxes paid (cash effect) (USD) -936,000 -969,000 -233,000 -400,000 0.00 0.00 -700,000 0.00 -6.1M -7.31M
Share-based compensation (USD) 7.85M 13.7M 20.5M 31.9M 31.6M 37M 48.9M 53.8M 53.3M 43.2M
Operating cash flow before change in receivables (USD) — — — — — — — -97.8M -170M -164M
Free cash flow (OCF - PPE - intangibles) (USD) 91.6M -41M -88.9M 53.3M -18.8M -32.8M -18.9M 63.9M -212M -138M
Income detail
Research and development expense (USD) 51.9M 71.8M 97.5M 119M 170M 193M 200M 254M 228M 239M
↳ 5y CAGR +41.5% +41.8% +45.0% +37.8% +30.0% +22.7% +21.1% +13.9% +7.1%
Total comprehensive income (USD) 22.7M -49.3M -69.6M 29M -70.4M 81M -60.6M -118M -238M -89.9M
Comprehensive income to owners (USD) 22.7M -49.3M -69.6M 29M -70.4M 81M -60.6M -118M -235M -89.7M
Reported Mar 1, 2017 Feb 28, 2018 Feb 26, 2019 Feb 25, 2020 Feb 27, 2023 Feb 27, 2023 Feb 29, 2024 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Xencor Reports Third Quarter 2026 Financial Results Bull 5 Bear 0 Results

-- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO --

-- Early dose-escalation data for plamotamab (CD20 x CD3) in rheumatoid arthritis to be presented during the ACR Convergence conference --

-- XmAb412 (TL1A x IL23p19) on track for initial healthy participant data in 1H27; XENITH-UC Phase 2b study of XmAb942 (anti-TL1A) in ulcerative colitis on track for primary endpoint analysis expected in 2H27 --

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 4, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026.

“Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a monotherapy and in combination with anti-PD(L)1 are underway, with evaluation of XmAb819 in additional ENPP3-positive tumor types also ongoing. We expect that the accelerating tempo of clinical development for XmAb819, and across our portfolio, may present multiple opportunities for continued momentum into the new year and throughout 2027. Based on our plans, by the end of 2027 we anticipate XmAb819 will be the third XmAb 2+1 bispecific antibody to enter a potential registration-enabling study, following xaluritamig and ASP2138,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “For our autoimmune portfolio, next week at the ACR Convergence conference we will present early dose-escalation data from the Phase 1 study of our CD20 x CD3 B-cell depleting T-cell engager, plamotamab, which we are evaluating in patients with rheumatoid arthritis following standard-of-care treatments.”

“For our two TL1A-targeting development programs, enrollment in XENITH-UC, the global Phase 2b study of XmAb942, is on track for the primary endpoint analysis in the second half of 2027, and for our novel TL1A x IL23p19 bispecific, XmAb412, we plan to present healthy participant data in the first half of 2027.”

Wholly Owned Pipeline Overview

XmAb819 (ENPP3 x CD3), a potential first-in-class, tumor-targeted, T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC) and other tumors with high ENPP3 expression, including colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma

  • As previously disclosed, in the first half of 2027 Xencor plans to engage with the FDA regarding a potential accelerated approval pathway for XmAb819 in subsets of patients with advanced ccRCC who have exhausted standard-of-care treatment options. Subject to regulatory feedback, by the end of 2027 Xencor also plans to initiate a global randomized Phase 3 study evaluating XmAb819 against tivozanib in patients with advanced ccRCC previously treated with one PD-(L)1 inhibitor and at least one VEGF receptor tyrosine kinase inhibitor (VEGFR TKI).

Ongoing Phase 1 Study in Patients with Advanced ccRCC

  • Expansion cohorts evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC have completed enrollment. Expansion cohort results were presented at the European Society For Medical Oncology (ESMO) Congress in October 2026. As of the October 1, 2026, data-cut, the efficacy-evaluable cohort at the 400 mcg/kg intravenous (IV) dose (n=11) reported five confirmed partial responses for a confirmed objective response rate of 45.5% per investigator assessment (RECIST v1.1), with one unconfirmed partial response for an unconfirmed objective response rate of 55%. Xencor has selected the 400 mcg/kg IV dose as the proposed IV recommended Phase 3 dose (RP3D) for advanced clinical development, based on maturing data from the 11 patients reported and from additional patients who have enrolled into this expansion cohort. As of the September 1, 2026 data-cut, which served as the foundation for the results presented at the ESMO 2026 Congress, XmAb819 was generally well tolerated in the combined expansion dose cohorts (n=68) with a manageable safety profile and a 5.9% rate of treatment discontinuation due to related treatment-emergent adverse events. Xencor plans to present additional results from the 400 mcg/kg IV cohort in the first half of 2027.

  • Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, and Xencor plans to present results in the first half of 2027.

Proof-of-Concept Sub-Studies to Enable Expansion of Development Are Ongoing

  • Part C of the ongoing Phase 1 study is enrolling patients with ENPP3+ advanced papillary RCC, colorectal cancer and non-small cell lung cancer.

  • Part D of the ongoing Phase 1 study is enrolling patients with IMDC intermediate- to poor-risk advanced ccRCC, who have progressed after nivolumab in combination with ipilimumab as a first-line treatment and who are naïve to VEGFR TKI therapy.

  • Part F of the ongoing Phase 1 study is planned as a safety study for the combination of XmAb819 with nivolumab to potentially enable front-line development.

XmAb541 (CLDN6 x CD3) in combination with XmAb808 (B7-H3 x CD28), in Phase 1 clinical development for T-cell engagement of Claudin-6 expressing tumors, including high-grade serous ovarian cancer

  • The Phase 1 dose-escalation study of XmAb541 and XmAb808 is ongoing and expected to reach the combination’s target dose range in 2027.

XmAb942 (Xtend™ anti-TL1A), a potential best-in-class, high-potency, extended half-life antibody in clinical development for patients with inflammatory bowel disease

  • Xencor is conducting the XENITH-UC Study, a global Phase 2b study of XmAb942 in ulcerative colitis (UC). XENITH-UC is a randomized, double-blind, placebo-controlled trial in patients with moderately to severely active UC, whose disease has progressed after at least one conventional or advanced therapy.

  • Enrollment expectations continue to support a XENITH-UC blinded interim analysis around year-end 2026 and reaching the primary endpoint analysis of the 12-week induction period in the second half of 2027. The primary endpoint of XENITH-UC is the percentage of patients achieving clinical remission defined by the modified Mayo score at week 12.

XmAb412 (TL1A x IL23p19), a potential best-in-class, extended half-life bispecific antibody for dual targeting of inflammatory pathways in autoimmune and inflammatory disease, in Phase 1 development and enrolling healthy participants

  • XmAb412 robustly suppresses both TL1A and IL-23 inflammatory pathways and is predicted to have a human half-life between 60 and 70 days. XmAb412 supports a high-concentration, low-viscosity and citrate-free formulation suitable for subcutaneous dosing. XmAb412 is Xencor’s first novel bispecific antibody developed using the XenLock™ platform.

  • The first-in-human study of XmAb412 is ongoing, and Xencor plans to present initial data from the study in the first half of 2027.

Plamotamab (CD20 x CD3), a clinical-stage, B-cell depleting bispecific T-cell engager in Phase 1 development for patients with rheumatoid arthritis (RA), who have progressed through prior standard-of-care treatment

  • Early dose-escalation data from the Phase 1b study were accepted for presentation during the American College of Rheumatology (ACR) Convergence conference in November 2026. A poster titled “Phase 1 Study of Plamotamab, a Bispecific CD20xCD3 T-cell Engager, in Adult Patients With Rheumatoid Arthritis: Interim Results” will be presented during the poster session “Rheumatoid Arthritis - Treatment Poster B” on Monday, November 9, 10:30 a.m. – 12:30 p.m. ET (Abstract 1417).

XmAb657 (CD19 x CD3), a clinical-stage, potent, extended half-life B-cell depleting bispecific T-cell engager in Phase 1 dose escalation, enrolling healthy participants and patients with idiopathic inflammatory myopathies, systemic sclerosis and Sjögren’s disease

  • Xencor plans to provide an update on progress achieved in the Phase 1 study of XmAb657 in the second half of 2026.

Recent Partnership Developments

  • **Amgen:**Amgen is advancing two Phase 3 studies of xaluritamig, a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). In August 2026, Amgen announced the completion of enrollment in XALute, a Phase 3 study evaluating xaluritamig as a monotherapy in patients with mCRPC previously treated with taxane-based chemotherapy. The Phase 3 XALience study is evaluating xaluritamig in combination with abiraterone versus investigator's choice therapy in patients with chemotherapy-naive mCRPC. Multiple earlier-phase studies are also evaluating xaluritamig as a monotherapy or in combination across additional prostate cancer treatment settings. At the ESMO 2026 Congress, Amgen presented results from a Phase 1 study of xaluritamig monotherapy and xaluritamig in combination with abiraterone in patients with mCRPC who have not yet received taxane-based chemotherapy. Amgen demonstrated that four- to six-hour fully outpatient monitoring after cycle 1 step-up dosing was feasible, supporting the potential for a more convenient administration setting. Xencor is eligible to receive up to $225 million in future milestone payments and tiered royalties on net sales that range from mid- to high-single digit percentages.

  • **Astellas:**In August 2026, Astellas announced that the first patient had been dosed in a Phase 3 clinical trial evaluating ASP2138 in combination with chemotherapy and pembrolizumab as a first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative, which triggered a $25.0 million milestone payment. ASP2138 is an investigational subcutaneously administered bispecific antibody designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells. ASP2138 utilizes Xencor’s XmAb 2+1 multivalent format. Xencor is eligible to receive up to $207.5 million in future milestone payments and tiered royalties on net sales that range from high-single to low-double digit percentages.

  • **Zenas BioPharma:**Zenas submitted a Biologics License Application (BLA) to the FDA for obexelimab for the treatment of IgG4-related disease (IgG4-RD) in May 2026, which was accepted for review in August 2026. In the third quarter of 2026, Zenas’ partner Bristol Myers Squibb submitted a marketing authorization application for obexelimab in IgG4-RD in Japan, which triggered a $2.5 million milestone payment. Obexelimab targets CD19 with its variable domain and uses an XmAb Immune Inhibitor Fc Domain. In November 2021, Xencor licensed obexelimab to Zenas, and under the license agreement, Xencor is eligible to receive up to $447.5 million in future milestone payments and tiered royalties on net sales that range from mid-single-digit to mid-teen percentages, dependent on geography. As of September 30, 2026, Xencor owned 1.0 million shares of common stock in Zenas.

**Financial Guidance:**Based on current operating plans, Xencor expects to end 2026 with between $480 million and $500 million in cash, cash equivalents and marketable debt securities, and to have sufficient cash resources to fund research and development programs and operations into 2029.

Financial Results for the Third Quarter Ended September 30, 2026

Cash, cash equivalents and marketable debt securities totaled $555.7 million as of September 30, 2026, compared to $610.8 million as of December 31, 2025. Under the settlement agreement with Alexion, Xencor received $52.5 million in August 2026 and is entitled to receive a final payment of $52.5 million in the third quarter of 2027. In addition, Xencor received $66.9 million in cash proceeds from the sales of an equity security.

Revenue for the third quarter ended September 30, 2026 was $116.5 million, compared to $21.0 million for the same period in 2025. Revenue earned in the third quarter of 2026 was primarily due to royalty revenue from Alexion and Incyte and milestone revenue from Astellas.

Research and development (R&D) expenses for the third quarter ended September 30, 2026 were $84.3 million, compared to $54.4 million for the same period in 2025. Increased R&D spending for the third quarter of 2026 compared to 2025 is primarily due to higher external and internal costs associated with development programs, partially offset by lower stock-based compensation expense in the current period.

General and administrative (G&A) expenses for the third quarter ended September 30, 2026 were $9.4 million, compared to $14.2 million for the same period in 2025. Decreased G&A spending for the third quarter of 2026 compared to 2025 is primarily due to a non-recurring recovery of legal expenses.

Other income, net, for the third quarter ended September 30, 2026 was $16.4 million, compared to $41.5 million for the same period in 2025. Decreased other income, net, for the third quarter of 2026, compared to 2025, is primarily due to lower unrealized gains on an equity security.

Net income attributable to Xencor for the third quarter ended September 30, 2026 was $39.4 million, or $0.50 on a fully diluted per share basis, compared to a net loss of $6.0 million, or $(0.08) on a fully diluted per share basis, for the same period in 2025.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “indicates,” “supports,” “on track,” “predicted,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding our expectations for regulatory and partnership milestone achievements, clinical pipeline advancements, planned receipt and presentations of clinical data, including the expected timing thereof, and planned and ongoing clinical trials, including the expected timing thereof, trial design, dose selection, expected results and discussions with regulatory authorities, including regarding potential accelerated approval pathways, enrollment, the potential for trials to be registrational, the potential therapeutic benefits and characteristics of Xencor’s and its partners’ product candidates, including predicted half-life and formulation, the clinical development and regulatory activities of Xencor’s partners, including the timing and outcome of regulatory reviews, Xencor’s eligibility to receive future milestone payments and royalties, projected financial resources and financial guidance, including estimated cash, cash equivalents and marketable debt securities at year end and cash runway for research and development programs and operations, expectations for and estimates of future royalty revenues, the quotations from Xencor's president and chief executive officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs for use as human therapeutics, the risk that publicly disclosed preliminary clinical trial data does not support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management, the risk that the fair value of our marketable equity securities may decline and the risks, uncertainties and other factors described under the heading “Risk Factors” in Xencor's Annual Report on Form 10-K for the year ended December 31, 2025 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

| Xencor, Inc. |

| Selected Consolidated Balance Sheet Data |

| (in thousands) |

| | | | |

| | September 30, | | December 31, |

| | 2026 | | 2025 |

| | (unaudited) | | |

| Cash, cash equivalents and marketable debt securities | $ | 555,690 | | $ | 610,833 |

| Other current assets | | 120,551 | | | 164,590 |

| Other long-term assets | | 94,264 | | | 100,072 |

| Total assets | $ | 770,505 | | $ | 875,495 |

| | | | |

| Liabilities related to the sales of future royalties | $ | 95,060 | | $ | 119,749 |

| Other current liabilities | | 53,133 | | | 52,640 |

| Non-current lease and other liabilities | | 61,877 | | | 67,519 |

| Total liabilities | | 210,070 | | | 239,908 |

| Total stockholders' equity | | 560,435 | | | 635,587 |

| Total liabilities and stockholders’ equity | $ | 770,505 | | $ | 875,495 |

| Xencor, Inc. |

| Consolidated Statements of Operations and Comprehensive Income (Loss) |

| (in thousands, except per share amounts) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| | (Unaudited) |

| Revenue | | | | | | | |

| Collaborations, milestones, and royalties | $ | 116,520 | | | $ | 20,999 | | | $ | 172,257 | | | $ | 97,339 | |

| Operating expenses: | | | | | | | |

| Research and development | | 84,297 | | | | 54,367 | | | | 220,871 | | | | 174,610 | |

| General and administrative | | 9,359 | | | | 14,151 | | | | 43,452 | | | | 46,603 | |

| Total operating expenses | | 93,656 | | | | 68,518 | | | | 264,323 | | | | 221,213 | |

| Operating income (loss) | | 22,864 | | | | (47,519 | ) | | | (92,066 | ) | | | (123,874 | ) |

| | | | | | | | |

| Total other income (expense) | | 16,397 | | | | 41,492 | | | | (19,228 | ) | | | 38,507 | |

| | | | | | | | |

| Income (loss) before income tax (benefit) expense and noncontrolling interest | | 39,261 | | | | (6,027 | ) | | | (111,294 | ) | | | (85,367 | ) |

| Income tax (benefit) expense | | (175 | ) | | | — | | | | (85 | ) | | | 117 | |

| Net income (loss) including noncontrolling interest | | 39,436 | | | | (6,027 | ) | | | (111,209 | ) | | | (85,484 | ) |

| | | | | | | | |

| Net loss attributable to noncontrolling interest | | — | | | | — | | | | — | | | | (214 | ) |

| Net income (loss) attributable to Xencor, Inc. | $ | 39,436 | | | $ | (6,027 | ) | | $ | (111,209 | ) | | $ | (85,270 | ) |

| | | | | | | | |

| Net income (loss) per share attributable to Xencor, Inc.: | | | | | | | |

| Basic | $ | 0.52 | | | $ | (0.08 | ) | | $ | (1.47 | ) | | $ | (1.15 | ) |

| Diluted | $ | 0.50 | | | $ | (0.08 | ) | | $ | (1.47 | ) | | $ | (1.15 | ) |

| | | | | | | | |

| Weighted-average shares used in calculating net income (loss) per share: | | | | | | | |

| Basic | | 76,215 | | | | 74,413 | | | | 75,777 | | | | 74,122 | |

| Diluted | | 78,353 | | | | 74,413 | | | | 75,777 | | | | 74,122 | |

| | | | | | | | |

| Other comprehensive income (loss), net of tax: | | | | | | | |

| Net unrealized (loss) gain on marketable debt securities | | (1,653 | ) | | | 900 | | | | (4,101 | ) | | | 1,821 | |

| Comprehensive income (loss) | | 37,783 | | | | (5,127 | ) | | | (115,310 | ) | | | (83,663 | ) |

| Less: comprehensive loss attributable to the noncontrolling interest | | — | | | | — | | | | — | | | | (214 | ) |

| Comprehensive income (loss) attributable to Xencor, Inc. | $ | 37,783 | | | $ | (5,127 | ) | | $ | (115,310 | ) | | $ | (83,449 | ) |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104228449/en/

Charles Liles [email protected]

For media: [email protected]

Source: Xencor, Inc.

Scroll to top

-- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 --

-- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population --

-- Management to host webcast Monday, October 26 at 7:00 a.m. ET / 4:00 a.m. PT --

PASADENA, Calif.--Oct. 25, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

-- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate --

-- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 --

-- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population --

-- Management to host webcast Monday, October 26 at 7:00 a.m. ET / 4:00 a.m. PT --

PASADENA, Calif.--(BUSINESS WIRE)--Oct. 25, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. Xencor also reported additional follow-up data supporting selection of 400 mcg/kg as the intravenous proposed recommended Phase 3 dose and outlined plans for potential registration-enabling development by the end of 2027.

“We are excited to share the XmAb819 Phase 1 dose expansion results presented at ESMO today, along with key additional data, supporting the potential to bring T-cell engagement to treatment of patients with advanced clear cell renal cell carcinoma. We plan to initiate a potential registration-enabling study next year,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “XmAb819 exemplifies our approach to engineering XmAb 2+1 bispecific antibodies for selective targeting of malignant cells in solid tumors, and we anticipate that it will become the third XmAb 2+1 candidate to advance into late-stage development. With cash runway into 2029, we are well positioned to continue to pursue an accelerated pace of clinical development across our portfolios in oncology and autoimmune disease.”

“XmAb819 has demonstrated impressive antitumor activity in a heavily pre-treated and difficult-to-treat patient population with advanced clear cell renal cell carcinoma,” said Dr. Pal, who is also a study investigator. “At present, available treatments for renal cell carcinoma include checkpoint inhibitors and targeted therapies along the VEGF axis. XmAb819 is an agent with a wholly distinct proposed mechanism of action as a potential first-in-class ENPP3-targeted T-cell engager. Given the unique proposed mechanism as well as the efficacy and tolerability results we have seen thus far, it is critical to explore this agent in earlier settings and in other ENPP3-expressing malignancies.”

Xencor will host a webcast tomorrow at 7:00 a.m. ET (4:00 a.m. PT) to discuss the updated results presented at ESMO, additional data and development plans for XmAb819. The live webcast may be accessed through this link and through “Events & Presentations” in the Investors section of the Company’s website, located at investors.xencor.com. A recording will be available for at least 30 days.

Updated Phase 1 Results of XmAb819 Presented at ESMO

As of the September 1, 2026 data-cut, the Phase 1 study enrolled a total of 119 patients with advanced ccRCC across 11 different intravenous (IV) target dose levels. XmAb819 is administered as a weekly priming regimen with escalating priming doses followed by the maintenance target dose.

Three target dose levels were chosen for expansion and evaluation as a proposed recommended Phase 3 dose (RP3D), 100 mcg/kg, 200 mcg/kg and 400 mcg/kg (Expansion Doses, n=68). Patients enrolled into the Expansion Dose cohorts were heavily pre-treated with a median of three prior lines of therapy and were predominantly intermediate- to poor-risk (94%) by the IMDC (International Metastatic RCC Database Consortium) risk model. All patients had received at least one prior PD-(L)1 inhibitor and at least one prior VEGFR TKI. In addition, 63% of patients were previously treated with two or more prior VEGFR TKIs, and 34% of patients were treated with at least one HIF2α inhibitor. Response rate increased with increasing dose across Expansion Doses, and all Expansion Doses were generally well tolerated.

| **Expansion Dose Cohort,**n1 | 100 mcg/kgn=30 | 200 mcg/kgn=25 | 400 mcg/kgn=11 |

| Confirmed Objective Response Rate (cORR)2(95% CI) | 30% (14.7% – 49.4%) | 44% (24.4% – 65.1%) | 45.5% (16.8% – 76.6%) |

| Disease Control Rate(95% CI) | 87% (69.3% – 96.2%) | 64% (42.5% – 82%) | 82% (48.2% – 97.7%) |

| Median Follow-up (months) | 4.1 | 4.5 | 6 |

| 1. Efficacy analysis includes patients with at least one protocol-specified dose of XmAb819 and at least one post-baseline tumor assessment. Two patients enrolled into the 200 mcg/kg cohort are excluded due to not having a post-baseline tumor assessment, and one patient enrolled into the 400 mcg/kg cohort is excluded for never receiving a protocol-specified dose of XmAb819. 2. Confirmed responses per investigator assessment, RECIST v1.1. |

Of the 25 patients with confirmed response per RECIST v1.1, one had a complete response, 24 had partial responses and 19 of the responses remained ongoing as of the data cut with a median time on treatment of 7 months (range, 3.4 – 28.3).

XmAb819 was generally well tolerated in the combined Expansion Dose cohorts with manageable adverse events and a low 5.9% rate of treatment discontinuation due to related treatment-emergent adverse events (TEAEs). Grade 3 or higher related TEAEs occurred in 72.1% of patients. The most common Grade 3 or higher TEAEs were liver enzyme elevations (aspartate aminotransferase (AST) increased, 35.3%; alanine aminotransferase (ALT) increased, 33.8%), rash (combined term, 22.1%), hypotension (7.4%) and cytokine release syndrome (CRS, 5.9%). TEAEs occurred primarily during the priming period, and after day 29 the most common Grade 3 or higher TEAEs that occurred were liver enzyme elevations (ALT increased, 10.3%; AST increased, 8.8%), rash (combined term, 2.9%) and diarrhea (2.9%).

Cytokine-related adverse events, such as CRS, rash and liver enzyme elevations, were well managed, transient and had limited impact on treatment. CRS did not lead to dose delays, and one patient discontinued treatment due to CRS. Rash (combined term) led to dose delays in 4.4% of patients with no treatment discontinuations. Transaminase elevations were asymptomatic, transient, and self-limited, with a median time to resolution of seven days and no clinical sequelae; dose delays occurred in 14.7% of patients with no treatment discontinuations.

Suspected dose preparation errors were limited to three patients in the Expansion Dose cohorts (3/69 patients). The Expansion Dose analysis set excludes one patient who never received a protocol-specified dose of XmAb819, experienced an approximately 10-fold higher exposure than intended at the first and only dose administered, subsequently developed Grade 4 CRS, fully recovered and discontinued treatment. All three events occurred prior to introduction of the new study drug formulation.

Management to Discuss Additional Data and Development Plans on Webcast

**As of a subsequent October 1, 2026 data-cut, the current efficacy evaluable cohort (n=11) at 400 mcg/kg IV reported 5 confirmed partial responses (cORR, 45.5%) and 1 unconfirmed partial response (uORR, 55%).**The median progression-free survival (PFS) estimate was not reached, and more than 70% of patients remained on treatment. The 6-month Kaplan-Meier estimate of PFS was 82%. The safety results were consistent with the 100 mcg/kg and 200 mcg/kg target dose cohorts.

Xencor has selected the IV dose of 400 mcg/kg as the proposed IV RP3D for advanced clinical development. The decision is based on maturing data from the efficacy evaluable cohort (n=11) and with additional patients who have enrolled into this expansion cohort. Xencor anticipates a total efficacy-evaluable patient population treated at 400 mcg/kg of at least 20 patients to be available to support dose selection during the first half of 2027.

**Xencor plans to discuss a potential accelerated approval pathway with the FDA in subsets of patients with advanced ccRCC who have exhausted standard of care.**A pooled analysis of the three Expansion Doses provided two patient subsets, patients who had progressed after prior treatment exposure to at least one PD-(L)1 inhibitor and at least two VEGFR TKIs (n=42) and “triple class exposed” patients with prior treatment exposure to at least one PD-(L)1 inhibitor, one VEGFR TKI and one HIF2α inhibitor (n=23).

As of the September 1, 2026 data-cut:

  • Efficacy evaluable patients enrolled with prior treatment exposure to at least one PD-(L)1 inhibitor and at least 2 or more VEGFR TKIs reported 18 confirmed partial responses and 1 confirmed complete response (45% cORR; 95% CI, 29.9% – 61.3%).

  • Efficacy evaluable “triple class exposed” patients with prior treatment exposure to at least one PD-(L)1 inhibitor, one VEGFR TKI and one HIF2α inhibitor reported 8 confirmed partial responses (35% cORR; 95% CI, 16.4% – 57.3%).

**Xencor plans to initiate a global randomized trial comparing XmAb819 with tivozanib as a control arm in advanced ccRCC patients who have prior treatment with one PD-(L)1 inhibitor and at least one VEGFR TKI.**Xencor anticipates that, subject to further interactions with FDA, this study, if successful, could serve as the basis for full approval of XmAb819 as a monotherapy in the second- and third-line treatment setting for patients with advanced ccRCC. In a sub-group analysis of the TiNivo-2 study in a similar treatment line (patients who were post PD-(L)1 and at least one VEGFR TKI), tivozanib achieved a median PFS of 5.4 months, a 6-month PFS Kaplan-Meier estimate of 41%and a cORR of 10.5%.1

Proof-of-concept sub-studies to enable expansion of XmAb819 development are ongoing.

  • Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, with anticipated results during the first half of 2027.

  • Part C of the ongoing Phase 1 study is enrolling patients with ENPP3+ advanced papillary RCC, colorectal cancer and non-small cell lung cancer.

  • Part D of the ongoing Phase 1 study is enrolling patients with IMDC intermediate- to poor-risk ccRCC, who have progressed after nivolumab in combination with ipilimumab as a first-line treatment and are naïve to VEGFR TKI therapy.

  • Part F of the ongoing Phase 1 study is planned as a safety study for the combination of XmAb819 with nivolumab to potentially enable front-line development.

Cohorts to evaluate every 3-week intravenous dosing and reduced hospitalization requirements are planned.

1 Reference: Motzer RJ, et al. Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of Tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC). Poster presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Poster 34. Cross-trial comparison is provided for illustration only and is not based on head-to-head studies; trials differ in design, population and response assessment, and strong caution should be exercised when comparing data across unrelated trials.

About XmAb819

XmAb819 is a potential first-in-class, tumor-targeted, T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC) and other tumors with high ENPP3 expression, including colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma. XmAb819 is designed to engage the immune system and to activate T cells for highly potent and targeted lysis of tumor cells expressing ENPP3. ENPP3 is a differentially expressed target, with high-level expression in renal cell carcinoma (RCC) and low-level expression on normal tissues. With two tumor-antigen binding domains and one T-cell binding domain, Xencor’s XmAb® 2+1 format is designed to enable antibodies to bind more avidly and selectively kill tumor cells with higher antigen density, potentially sparing normal cells. XmAb819 is being evaluated in a Phase 1 clinical study, and Xencor plans to initiate a potential registration-enabling study of XmAb819 as a monotherapy in advanced ccRCC by the end of 2027. Clinical development also includes evaluation of subcutaneous administration, combination therapy, and in additional ENPP3-expressing tumor types.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “indicates,” “supports,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding expectations for clinical progress, planned presentations of clinical data, planned and in process clinical trials, including trial design, timing for initiation or disclosing results, potential results, dose selection, expected results and discussions with regulatory authorities, Xencor’s cash runway, any potential accelerated approval or pathway, the potential for trials to be registrational, any potential approvals, the quotations from Xencor's president and chief executive officer and the study investigator, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments and the risks, uncertainties and other factors described under the heading “Risk Factors” in Xencor's annual report on Form 10-K for the year ended December 31, 2025 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261025921014/en/

Charles Liles [email protected]

For media: [email protected]

Source: Xencor, Inc.

Scroll to top

Prompts

Xencor, Inc. (ticker XNCR), listed in United States.

ETFs Holding Xencor, Inc.

ETF Weight in ETF Shares Market value As of
ESSC 0.33% 5,914 $ 119.522K Jul 31, 2026
AVSC 0.19% 170,765 $ 6.045M Nov 16, 2026
TMSL 0.06% 93,250 $ 1.501M Jun 30, 2026
RESM 0.04% 82 $ 1,320.20 Jun 30, 2026
SMDX 0.03% 1,031 $ 36.497K Nov 17, 2026
FESM 0.03% 106,183 $ 1.71M Jun 30, 2026
DFAS 0.03% 231,632 $ 8.832M Nov 12, 2026
DFAC 0.01% 245,819 $ 9.373M Nov 12, 2026
AVSU 0.01% 1,032 $ 36.533K Nov 16, 2026
DCOR 0.01% 84,684 $ 3.229M Nov 12, 2026
DFAU 0.01% 18,347 $ 699.571K Nov 12, 2026
DFUS 0.01% 30,093 $ 1.147M Nov 12, 2026
DFSU 0.00% 2,577 $ 98.261K Nov 12, 2026
DXUV 0.00% 1,941 $ 74.01K Nov 12, 2026
AVUS 0.00% 14,480 $ 512.592K Nov 16, 2026
NTRL short 0.00% -4,029 $ 0.00 Nov 16, 2026